Table of Contents
Executive summary
- Cancer innovations are driving pharmaceutical industry growth
- Key innovations and technologies
- Key therapy areas and applications
- Key companies and pipelines
- Key trends and implications
Chapter 1 Cancer innovations driving pharma growth
- Summary
- Introduction
- Definitions
- Historical performance
- Impact of cancer market on industry as a whole
Chapter 2 Key innovations and technologies
- Summary
- Introduction
- Oncology treatment pathways
- Chemotherapeutics
- Hormonals
- Monoclonal antibodies
- Targeted therapies
- Immunotherapy and vaccines
- Leading marketed technologies
- Rituxan/ MabThera
- Herceptin
- Gleevec/ Glivec
- Avastin
- Eloxatin
- Erbitux
- Xeloda
- Femara
- Temodar
- Tarceva
- Leading new technologies for the future
- Kinase inhibitors
- Tubulin and microtubule inhibitors
- Topoisomerase inhibitors
- Cluster of differentiation receptor agonists
- DNA polymerase inhibitors
Chapter 3 Key therapy areas and applications
- Summary
- Introduction
- Key therapy areas
- Current treatment protocols and unmet needs
- Lung cancer
- Colorectal cancer
- Lymphomas
- Leukemia
- Breast cancer
- Likely future breakthroughs
- Alimta
- Gardasil
- Sutent
- Abraxane
- Nexavar
- Vectibix
- Sprycel
- Tykerb
- Cervarix
- MDX-010
Chapter 4 Key companies and pipelines
- Summary
- Introduction
- Leading players
- Leading oncology strategies
- Lifecycle management growth
- Diversification growth
- Novartis
- Pfizer
- Bristol-Myers Squibb
- Franchise development growth
- Sanofi-Aventis
- Schering-Plough
- Eli Lilly
- New market entry growth
- Merck
- Bayer Schering
- Amgen
- GlaxoSmithKline
Chapter 5 Key trends and implications
- Summary
- Introduction
- Future market growth
- Market opportunity
- Availability of effective treatments
- Leading technologies of tomorrow
- Key oncology success factors
- Lifecycle management
- New product development
- Index
List of Figures
- Figure 1.1: Global cancer innovatives market, 2003-2006
- Figure 1.2: Total pharmaceutical market and oncologics sales, 2004-2006
- Figure 1.3: Total oncologics and cancer innovatives sales, 2004-2006
- Figure 2.4: Leading cancer innovatives products, 2005-2006
- Figure 2.5: Rituxan/ MabThera (rituximab), 2003-2006
- Figure 2.6: Herceptin (trastuzumab), 2003-2006
- Figure 2.7: Gleevec/ Glivec (imatinib), 2003-2006
- Figure 2.8: Avastin (bevacizumab), 2003-2006
- Figure 2.9: Eloxatin (oxaliplatin), 2003-2006
- Figure 2.10: Erbitux (cetuximab), 2003-2006
- Figure 2.11: Xeloda (capecitabine), 2003-2006
- Figure 2.12: Femara (letrozole), 2003-2006
- Figure 2.13: Temodar (temozolomide), 2003-2006
- Figure 2.14: Tarceva (erlotinib), 2003-2006
- Figure 2.15: Cancer innovations by mode of action, 2007
- Figure 3.16: Cancer incidence in US, 2007
- Figure 3.17: Cancer deaths in US, 2007
- Figure 3.18: Cancer mortality rates in US, 2007
- Figure 3.19: New cancer deaths in US, 2007-2012
- Figure 3.20: Unmet needs in cancer markets across seven major markets, 2005
- Figure 3.21: Alimta (pemetrexed), 2004-2007
- Figure 3.22: Gardasil (human papillomavirus vaccine), 2006-2007
- Figure 3.23: Sutent (sunitinib), 2006-2007
- Figure 3.24: Abraxane (paclitaxel), 2005-2007
- Figure 3.25: Nexavar (sorafenib), 2006-2007
- Figure 3.26: Vectibix (panitumumab), 2006-2007
- Figure 3.27: Sprycel (dasatinib), 2006-2007
- Figure 4.28: Leading cancer innovatives companies, 2006-2007
- Figure 4.29: Genentech' s cancer innovatives, 2003-2006
- Figure 4.30: Roche' s cancer innovatives, 2003-2006
- Figure 4.31: Novartis' s cancer innovatives, 2003-2006
- Figure 4.32: Pfizer' s cancer innovatives, 2003-2006
- Figure 4.33: Bristol-Myers Squibb' s cancer innovatives, 2003-2006
- Figure 4.34: Sanofi-Aventis' s cancer innovatives, 2003-2006
- Figure 4.35: Schering-Plough' s cancer innovatives, 2003-2006
- Figure 4.36: Eli Lilly' s cancer innovatives, 2003-2006
- Figure 5.37: Cancer innovatives market forecast, 2003-2011
- Figure 5.38: New vs. established cancer innovatives market growth,
2003-2011
- Figure 5.39: Leading cancer innovatives drug classes, 2003-2011
- Figure 5.40: Leading cancer innovatives drugs, 2011
List of Tables
- Table 1.1: Global cancer innovatives market, 2003-2006
- Table 2.2: Leading cancer innovatives products, 2003-2006
- Table 2.3: Rituxan/ MabThera (rituximab) profile
- Table 2.4: Herceptin (trastuzumab) profile
- Table 2.5: Gleevec/ Glivec (imatinib) profile
- Table 2.6: Avastin (bevacizumab) profile
- Table 2.7: Eloxatin (oxaliplatin) profile
- Table 2.8: Erbitux (cetuximab) profile
- Table 2.9: Xeloda (capecitabine) profile
- Table 2.10: Femara (letrozole) profile
- Table 2.11: Temodar (temozolomide) profile
- Table 2.12: Tarceva (erlotinib) profile
- Table 3.13: Top 10 future breakthrough cancer innovatives
- Table 3.14: Future breakthrough cancer innovatives firsts...
- Table 3.15: Alimta (pemetrexed) profile
- Table 3.16: Gardasil (human papillomavirus vaccine) profile
- Table 3.17: Sutent (sunitinib) profile
- Table 3.18: Abraxane (paclitaxel) profile
- Table 3.19: Nexavar (sorafenib) profile
- Table 3.20: Vectibix (panitumumab) profile
- Table 3.21: Sprycel (dasatinib) profile
- Table 3.22: Tykerb (lapatinib) profile
- Table 3.23: Cervarix (human papillomavirus vaccine) profile
- Table 3.24: MDX-010 (ipilimumab) profile
- Table 4.25: Leading cancer innovatives companies, 2003-2006
- Table 4.26: Genentech' s cancer innovatives profile
- Table 4.27: Genentech' s cancer innovatives profile (continued)
- Table 4.28: Roche' s cancer innovatives profile
- Table 4.29: Roche' s cancer innovatives profile (continued)
- Table 4.30: Novartis' s cancer innovatives profile
- Table 4.31: Novartis' s cancer innovatives profile (continued)
- Table 4.32: Pfizer' s cancer innovatives profile
- Table 4.33: Pfizer' s cancer innovatives profile (continued)
- Table 4.34: Bristol-Myers Squibb' s cancer innovatives profile
- Table 4.35: Sanofi-Aventis' s cancer innovatives profile
- Table 4.36: Sanofi-Aventis' s cancer innovatives profile (continued)
- Table 4.37: Schering-Plough' s cancer innovatives profile
- Table 4.38: Eli Lilly' s cancer innovatives profile
- Table 4.39: Merck' s cancer innovatives profile
- Table 4.40: Bayer Schering' s cancer innovatives profile
- Table 4.41: Amgen' s cancer innovatives profile
- Table 4.42: GlaxoSmithKline' s cancer innovatives profile
|
Related Report
|
View Cart
